Semnurpharma - Getting back to normalSemnurpharmaSemnurpharmaSemnurpharma

Getting back to normal

  • About
    • Overview
    • Leadership Team
    • Board of Directors
    • Our Culture
  • Partners
  • Chronic Back Pain
    • Chronic Back Pain
    • SP-102 (SEMDEXA™)
    • About our Studies
      • Phase 3 C.L.E.A.R.-2 Study
      • Phase 3 C.L.E.A.R. Study
      • Phase 2 Repeat Dose Study – SP102-03
      • Phase 1 PK/PD and Safety Study – SP-102
      • Pre-Clinical Study – SP-102
  • Science
    • Technology
    • Publications
    • Clinical Trials
  • Investors
    • Investor Overview
    • Presentation
    • News and Events
    • SEC Filings
    • Analyst Coverage
    • Contact Investor Relations
  • Join Our Team
  • Contact Us

Author Archives: uferes@scilexholding.com

02
Jul
Date July 2, 2024

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination

Semnur Pharmaceuticals, Inc. (“Semnur”), a wholly owned subsidiary of Scilex Holding Company ...
Read More
Author uferes@scilexholding.com
14
Jun
Date June 14, 2024

A randomized, placebo-controlled trial of long-acting dexamethasone viscous gel delivered by transforaminal injection for lumbosacral radicular pain

...
Read More
Author uferes@scilexholding.com
02
Nov
Date November 2, 2023

Scilex Holding Company Announces Positive Type C Meeting with the FDA and Reaches Agreement on Path Forward to File an NDA for SP-102 (SEMDEXATM) in Lumbosacral Radicular Pain (Sciatica)

...
Read More
Author uferes@scilexholding.com
12
Jul
Date July 12, 2022

The pharmacokinetics andpharmacodynamics of dexamethasonefollowing epidural SP-102 orintravenous dexamethasone sodiumphosphate injection in subjects withlumbosacral radicular pain

...
Read More
Author uferes@scilexholding.com
05
May
Date May 5, 2022

Results from a Pivotal Phase 3, DB, R, Placebo-controlled, Multicenter Trial of SP-102, a Novel Dexamethasone Injectable Formulation, for the Treatment of Patients with Lumbosacral Radiculopathy (Sciatica)

...
Read More
Author uferes@scilexholding.com
18
Mar
Date March 18, 2022

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Final Results for SP-102 (SEMDEXA™) Efficacy and Safety from its Pivotal Phase 3 Clinical Trial Program for Sciatica Pain Management Supporting the Potential for First to Market Opportunity

...
Read More
Author uferes@scilexholding.com
09
Dec
Date December 9, 2021

Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary, Announces Highly Significant Positive Top-Line Results from its Phase 3 Non-Opioid Injectable SP-102 (SEMDEXA™) Pivotal Trial C.L.E.A.R. Program for Sciatica Pain Management

...
Read More
Author uferes@scilexholding.com
05
May
Date May 5, 2021

Repeat Epidural Injections of SP-102(Dexamethasone Sodium Phosphate InjectableGel) in Subjects with Lumbosacral Radiculopathy

...
Read More
Author uferes@scilexholding.com
27
Jan
Date January 27, 2021

Stephen Ma

Stephen Ma serves as the Chief Financial Officer and Senior Vice President since September 2023. Pri...
Read More
Author uferes@scilexholding.com
07
Oct
Date October 7, 2020

Scilex Holding Company, a Subsidiary of Sorrento Therapeutics, Announces Continuous Sales Growth in ZTlido® and Expects to Complete Enrollment on its SP-102 (SEMDEXA™) Phase 3 Pivotal Trial Program in 2020« back

...
Read More
Author uferes@scilexholding.com
1 2 3 Next page

 

  • Overview
  • Partners
  • Our Culture
  • Product
  • Publications
  • Join Our Team
  • Presentation
  • Contact Us

Connect, follow and have a conversation with us

  • 960 San Antonio Road, Palo Alto, CA, 94303
  • (650) 516-4310
  • info@semnurpharma.com

Privacy Policy | Terms of Use | © 2025 All rights reserved.

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces on November 6th, 2024 the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali.

Check Our Press Release

Scilex Holding

Semnur Pharmaceuticals

Denali Capital

… heavy objects, or some other non-specific back injury.

Reference:
@srinipillay 2016: https://www.health.harvard.edu/blog/psychology-low-back-pain-201604259537

Reference:
@srinipillay 2016: https://www.health.harvard.edu/blog/psychology-low-back-pain-201604259537

Reference:
@srinipillay 2016:https://www.health.harvard.edu/blog/psychology-low-back-pain-201604259537

The overall estimated number of epidural steroid injection (ESI) procedures in the U.S. is approximately 12.1 million across all Medicare and private coverage patients, with lumbar radiculopathy/sciatica procedures comprising approximately 88% of all ESIs administered, according to a proprietary study by Syneos Health. *

References:
*  Syneos Health